Business combination creates 5th largest generics business in the US

8 May 2018

Anmeal and Impax create diversified pharmaceutical company.

Amneal Pharmaceuticals LLC and Impax Laboratories Inc. have completed their business combination to form Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company"). As a diversified company with a robust generics business, Amneal is now the 5th largest generics business in the US, with a growing, high-margin specialty franchise.

Business combination creates 5th largest generics business in the US

Shares of Impax ceased trading on the NASDAQ stock exchange on 4 May 2018. Amneal will begin trading today on the New York Stock Exchange (NYSE) under the ticker "AMRX". Pursuant to the business combination agreement, each share of Impax common stock was converted into the right to receive one share of Amneal Class A common stock.

"We are very excited for the future of Amneal, and strongly believe that with our team, differentiated product portfolio, extensive R&D and manufacturing infrastructure and expertise, Amneal is well positioned to become an industry leader," said Chirag Patel and Chintu Patel, Co-Founders and Co-Chairmen of Amneal. "We are very proud of the Company we have built and look forward to Amneal's continued success under Rob Stewart's leadership."

Robert Stewart, President and CEO of Amneal, said: "As we enter our next stage of growth, we look forward to implementing our integration plans and quickly starting to realize the many benefits of this combination. We will promptly begin to leverage our enhanced product portfolio to fuel organic growth while capturing numerous synergies to unlock value and generate strong cash flow to support the rapid repayment of debt and further investment in growth opportunities."

The Company expects to benefit from its expanded product portfolio, differentiated pipeline and cost-efficient global manufacturing and development capabilities in nearly all dosage forms. Amneal expects to generate annual double-digit revenue and adjusted EPS growth and to achieve annual cost synergies of approximately $200 million within 3 years.

"This is a truly transformative combination that firmly establishes Amneal as an industry leader, with high-value generic product pipelines and a growing specialty business," said Paul Bisaro, Executive Chairman of Amneal. "With our combined resources, we are well-positioned to execute our plans to bring high-quality, affordable medicines to patients and generate long-term returns for our shareholders."

Review of the Strategic and Financial Benefits of the Combination

  • The Company currently has a generics portfolio with more than 200 differentiated product families marketed in nearly all dosage forms and holds a number one or number two position in a significant number of its marketed products, and has a growing specialty franchise targeting CNS disorders and anti-parasitic infections.
  • The generic products pipeline is currently one of the largest in the US, including approximately 149 ANDAs filed at the FDA and 135 projects in active stages of development, with nearly half of all pipeline products exclusive first-to-file, first-to-market or other high-value opportunities with three or fewer competitors estimated at the time of launch. In addition, the Company has a foundation for commercial entry into biosimilars through in-licensed products in various stages of development.
  • The Company is committed to ongoing investments in R&D with an expected annual investment of approximately 10% of net revenues, with a focus on the strategic development of high-value products within generics and specialty pharmaceuticals. The Company has an extensive, diversified global supply chain supporting capabilities across nearly all dosage forms including solid oral dose, softgels, injectables, topicals, transdermals, inhalation, complex molecules and drug-device combinations, with R&D and manufacturing sites in the US, India and Ireland.
  • The Company expects to generate annual double-digit growth in net revenue, adjusted EBITDA and adjusted EPS over the next 3 years.
  • The Company expects to achieve significant annual cost saving opportunities of approximately $200 million within 3 years. The majority of the savings will result from the complementary nature of the companies' combined operations as well as margin-enhancing product transfer opportunities.
  • Read More

    Related news

    Compact serialization-ready manual workstation

    Compact serialization-ready manual workstation

    11 Aug 2018

    A cost-effective and space-saving solution for serializing cartons and performing multi-level aggregation on cases and pallets.

    Read more 
    Oxford Genetics signs major supply and licensing agreement for CRISPR engineered mammalian cell lines

    Oxford Genetics signs major supply and licensing agreement for CRISPR engineered mammalian cell lines

    8 Aug 2018

    Company moves away from manual processing in favour of automated, scalable platforms.

    Read more 
    BASF receives award for its portfolio of natural cosmetic ingredients

    BASF receives award for its portfolio of natural cosmetic ingredients

    7 Aug 2018

    Company recognised for its innovation and continual delivery of new natural ingredients.

    Read more 
    Extended distribution agreement enables customers to continuously improve their bioprocesses

    Extended distribution agreement enables customers to continuously improve their bioprocesses

    6 Aug 2018

    Agreement includes Pall's next-generation Kaneka KanCapA 3G sorbent for the primary capture of mAbs from clarified cell culture.

    Read more 
    A new era for migraine patients

    A new era for migraine patients

    6 Aug 2018

    EU approves Novartis's Aimovig, a first-of-its-kind treatment specifically designed for migraine prevention.

    Read more 
    Amgen breaks ground on next-generation biomanufacturing plant in Rhode Island

    Amgen breaks ground on next-generation biomanufacturing plant in Rhode Island

    3 Aug 2018

    The plant will be first-of-its-kind in the US.

    Read more 
    Croda invests in SiSaf’s novel bio-courier technology

    Croda invests in SiSaf’s novel bio-courier technology

    3 Aug 2018

    ProSilic will give Croda’s customers access to the next generation of targeted and controlled drug delivery.

    Read more 
    Breast cancer device receives FDA approval

    Breast cancer device receives FDA approval

    3 Aug 2018

    The first non-radioactive, dual-tracer for sentinel lymph node biopsy approved in the US.

    Read more 
    Building contingency plans for an ambiguous post-Brexit market

    Building contingency plans for an ambiguous post-Brexit market

    31 Jul 2018

    One company's positive approach to Brexit preparations, despite the lack of definition.

    Read more 
    Cherwell publishes guide on environmental monitoring processes and validation

    Cherwell publishes guide on environmental monitoring processes and validation

    31 Jul 2018

    Supporting EM programs in preparation for proposed EU GMP Annex 1 changes.

    Read more